Fortress Biotech Inc FBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FBIO is a good fit for your portfolio.
News
-
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
-
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
-
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
-
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
-
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
-
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
-
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
-
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
Trading Information
- Previous Close Price
- $1.81
- Day Range
- $1.71–1.86
- 52-Week Range
- $1.24–12.00
- Bid/Ask
- $1.75 / $1.85
- Market Cap
- $33.66 Mil
- Volume/Avg
- 186,242 / 303,887
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 186
- Website
- https://www.fortressbiotech.com
Comparables
Valuation
|
Metric
|
FBIO
|
VRCA
|
CRNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.21 | 14.81 | 5.44 |
Price/Sales | 0.17 | 61.06 | 622.39 |
Price/Cash Flow | — | — | — |
Price/Earnings
FBIO
VRCA
CRNX
Financial Strength
|
Metric
|
FBIO
|
VRCA
|
CRNX
|
|---|---|---|---|
Quick Ratio | 1.13 | 4.34 | 12.92 |
Current Ratio | 1.38 | 4.55 | 13.07 |
Interest Coverage | −12.15 | −16.60 | — |
Quick Ratio
FBIO
VRCA
CRNX
Profitability
|
Metric
|
FBIO
|
VRCA
|
CRNX
|
|---|---|---|---|
Return on Assets (Normalized) | −64.86% | −70.68% | −38.81% |
Return on Equity (Normalized) | −499.38% | −112.62% | −44.79% |
Return on Invested Capital (Normalized) | −123.14% | −77.30% | −45.62% |
Return on Assets
FBIO
VRCA
CRNX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yqkqlvqn | Gwvd | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Blxczjtt | Hqdftv | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pgdhprjt | Ccrtly | $98.1 Bil | |
MRNA
| Moderna Inc | Rtpqdvw | Rsq | $39.1 Bil | |
ARGX
| argenx SE ADR | Nzvjhzcc | Mnvx | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Bcggzlrd | Glq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vnjdxspq | Qpfftx | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jsygpbfvk | Wxtxjd | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pfbrdmvjby | Qklkzp | $12.5 Bil | |
INCY
| Incyte Corp | Vqwrfgvz | Rxdqdqh | $11.9 Bil |